RESEARCHER PROFILE
Dr Mark Adams, Senior Research Fellow
School of Biomedical Sciences & Centre for Genomics and Personalised Health
Queensland University of Technology (QUT)
Dr. Mark Adams is a researcher at Queensland University of Technology, working within the School of Biomedical Sciences and Faculty of Health, as well as the Centre of Genomics and Personalised Health. He has been with the university for the past decade, and his main research focus is on lung cancers. Dr. Adams completed his undergraduate studies at the Queensland University of Technology and then went on to earn his PhD based at the Mater Research Institute at the Mater hospital. His PhD focused on prostate cancer and specifically looked at developing drugs that would stop the metastasis of prostate cancer towards the bone.
After completing his PhD, Dr. Adams returned to Queensland University of Technology to commence a postdoctoral fellowship. During his fellowship, he looked at lung cancer and how our genomes are maintained through a process called DNA repair. Dr. Adams has been successful in attracting funding to support his salary through fellowship support from foundations such as Cure Cancer, National Health and Medical Research Council, and the Queensland government.
Dr. Adams’ research focus is on lung cancer, which is the deadliest of all cancers worldwide. He is working towards developing personalised approaches to pinpoint a therapy that is going to be most effective for the person with that disease. Dr. Adams’ research is focusing on chemotherapy and targeted therapy, and he is trying to identify upfront which of those tumours are likely to be resistant to the therapy. He then identifies strategies that will resensitize or increase the sensitivity of the tumour to the standard of care that is targeted therapy or chemotherapy.
Dr. Adams’ research is driven by his fascination with trying to understand how something works and, in particular, understanding cells and the molecular mechanisms underpinning how those cells work. He has always been interested in biology and was drawn to the problem of cancer and what’s going on in those tumour cells that promote tumorigenesis.
Dr. Adams has a young family with three kids, all in primary school. He enjoys downhill mountain biking in the forest and playing futsal on Monday nights.
-
Exercise therapy for metabolic dysfunction-associated steatotic liver disease
Dr Shelley Keating is a Senior Lecturer in Clinical Exercise Physiology and Accredited Exercise Physiologist from the School of Human Movement and Nutrition Sciences at the University of Queensland. With a strong grounding in exercise metabolism and body composition, Dr Keating’s research centres on the utility of exercise as a therapy for obesity and related cardiometabolic conditions, notably metabolic dysfunction-associated steatotic liver disease (MASLD).
-
ROCK-induced early-onset bowel cancer progression
Professor Michael Samuel is a cell biologist whose research interest is in understanding how cancer mechanobiology influences the tumour microenvironment, thereby promoting tumour progression. He is Professor of Matrix Biology at the University of South Australia, Adelaide and heads the Tumour Microenvironment Laboratory at the Centre for Cancer Biology and the Cancer Mechanotherapies Laboratory at the Basil Hetzel Institute for Translational Health Research.
-
Identification & characterisation of molecular drivers of therapeutic resistance
Professor Pieter Eichhorn is an internationally experienced cancer biologist and research leader whose career has been defined by high-impact contributions at the interface of functional genomics, translational oncology, and research infrastructure strategy.
He completed his PhD at the University of Newcastle upon Tyne, contributing to the cloning of the gene associated with Cornelia de Lange Syndrome, before undertaking postdoctoral training at the Netherlands Cancer Institute in the laboratory of René Bernards. There, he performed pioneering functional genetic screens that identified key regulators of oncogenesis and therapy resistance, including critical roles for the PI3K signalling pathway in resistance to targeted breast cancer therapies.
